Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Oct 1.

Published in final edited form as: Invest New Drugs. 2010 Mar 16;29(5):719–729. doi: 10.1007/s10637-010-9407-5

Fig. 3 — a PABA/NO resistant cells are less sensitive to the cytotoxic effects of PABA/NO. 2×10⁴ cells (■) HL60 or () HL60^PABA were treated with a 10 uM or b 20 uM PABA/NO. Collateral resistance was assessed by treating the cells with c 300 nM thapsigargin or d 5 uM cisplatin. The total number of cells was counted and cell viability plotted as a function of time. Statistically significant differences were determined using Student’s t test and are indicated by, p-value <0.05

Inline graphic — a PABA/NO resistant cells are less sensitive to the cytotoxic effects of PABA/NO. 2×10⁴ cells (■) HL60 or () HL60^PABA were treated with a 10 uM or b 20 uM PABA/NO. Collateral resistance was assessed by treating the cells with c 300 nM thapsigargin or d 5 uM cisplatin. The total number of cells was counted and cell viability plotted as a function of time. Statistically significant differences were determined using Student’s t test and are indicated by, p-value <0.05